Published in J Clin Invest on March 08, 2007
TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol (2009) 2.15
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A (2008) 1.36
Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
Inhibition of autophagy impairs tumor cell invasion in an organotypic model. Cell Cycle (2012) 1.14
Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Dis (2010) 1.10
Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res (2008) 1.03
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res (2015) 1.03
Loss of autophagy causes a synthetic lethal deficiency in DNA repair. Proc Natl Acad Sci U S A (2015) 1.02
iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. BMC Cancer (2010) 1.02
DRAM-1 encodes multiple isoforms that regulate autophagy. Autophagy (2012) 0.99
The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer (2013) 0.94
Oncogene-induced sensitization to chemotherapy-induced death requires induction as well as deregulation of E2F1. Cancer Res (2010) 0.94
Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73. Cancer Biol Ther (2008) 0.93
Pharmacological activation of p53 in cancer cells. Curr Pharm Des (2011) 0.92
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer (2010) 0.92
p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90
Structural basis for ASPP2 recognition by the tumor suppressor p73. J Mol Biol (2012) 0.83
Tumor antigen LRRC15 impedes adenoviral infection: implications for virus-based cancer therapy. J Virol (2008) 0.82
JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress. Cell Death Dis (2014) 0.81
p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death. Oncogene (2015) 0.80
A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity. Cell Death Dis (2015) 0.79
Graft-versus-host disease-related cytokine-driven apoptosis depends on p73 in cytokeratin 15-positive target cells. Biol Blood Marrow Transplant (2012) 0.75
Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo. Oncotarget (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Surfing the p53 network. Nature (2000) 35.36
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
A model for p53-induced apoptosis. Nature (1997) 11.38
PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 11.04
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell (2001) 7.95
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther (1996) 7.12
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell (2001) 4.38
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet (2002) 3.57
Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev (1995) 3.40
p73: Friend or foe in tumorigenesis. Nat Rev Cancer (2002) 3.30
p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem (2003) 2.69
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A (1994) 2.37
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17
p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
TP53 family members and human cancers. Hum Mutat (2003) 1.70
Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol (1998) 1.51
p73alpha regulation by Chk1 in response to DNA damage. Mol Cell Biol (2003) 1.36
The expression of iASPP in acute leukemias. Leuk Res (2005) 1.16
Splicing DNA-damage responses to tumour cell death. Biochim Biophys Acta (2004) 1.16
Therapeutic exploitation of the p53 pathway. Trends Mol Med (2002) 1.15
p53, p63 and p73--solos, alliances and feuds among family members. Biochim Biophys Acta (2001) 1.15
Evolution of functions within the p53/p63/p73 family. Ann N Y Acad Sci (2000) 1.13
The ASPP family: deciding between life and death after DNA damage. Toxicol Lett (2003) 1.08
The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res (2002) 1.05
DNA-binding independent cell death from a minimal proapoptotic region of E2F-1. Oncogene (2006) 1.02
The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene (2004) 1.00
Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res (2005) 0.96
53BP2 induces apoptosis through the mitochondrial death pathway. Genes Cells (2005) 0.93
Relief of p53-mediated telomerase suppression by p73. J Biol Chem (2005) 0.92
The tumour-suppressor protein ASPP1 is nuclear in human germ cells and can modulate ratios of CD44 exon V5 spliced isoforms in vivo. Oncogene (2006) 0.91
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell (2006) 11.85
DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell (2006) 9.47
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
Genome sequencing and analysis of the versatile cell factory Aspergillus niger CBS 513.88. Nat Biotechnol (2007) 6.21
Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell (2003) 5.44
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
p53 mutations in cancer. Nat Cell Biol (2013) 5.18
p53 and metabolism. Nat Rev Cancer (2009) 5.05
Total knee arthroplasty volume, utilization, and outcomes among Medicare beneficiaries, 1991-2010. JAMA (2012) 4.89
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Improved response to disasters and outbreaks by tracking population movements with mobile phone network data: a post-earthquake geospatial study in Haiti. PLoS Med (2011) 4.38
Availability of consumer prices from US hospitals for a common surgical procedure. JAMA Intern Med (2013) 4.35
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77
The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab (2010) 3.61
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
p73: Friend or foe in tumorigenesis. Nat Rev Cancer (2002) 3.30
A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol (2008) 3.13
Clinical characteristics and outcomes of Medicare patients undergoing total hip arthroplasty, 1991-2008. JAMA (2011) 3.09
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res (2007) 3.08
p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem (2003) 2.69
p53: new roles in metabolism. Trends Cell Biol (2007) 2.69
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics. Cancer Res (2007) 2.60
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 2.45
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet (2003) 2.41
Impact of telemedicine intensive care unit coverage on patient outcomes: a systematic review and meta-analysis. Arch Intern Med (2011) 2.41
The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J (2005) 2.38
Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med (2010) 2.32
Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J (2009) 2.31
Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci (2003) 2.29
Glycogen synthase kinase-3beta positively regulates the proliferation of human ovarian cancer cells. Cell Res (2006) 2.29
Metabolic regulation by p53. J Mol Med (Berl) (2011) 2.26
The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China. J Virol (2011) 2.23
iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet (2006) 2.20
Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell (2005) 2.17
The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol (2007) 2.13
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. EMBO J (2006) 2.11
Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10
TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell (2013) 2.03
Metabolic regulation by p53 family members. Cell Metab (2013) 2.00
Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc Natl Acad Sci U S A (2012) 1.97
INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J (2002) 1.96
Analysis of DRAM-related proteins reveals evolutionarily conserved and divergent roles in the control of autophagy. Cell Cycle (2009) 1.95
C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol (2007) 1.94
The association between hospital obstetrical volume and maternal postpartum complications. Am J Obstet Gynecol (2012) 1.90
ASPP1 and ASPP2: common activators of p53 family members. Mol Cell Biol (2004) 1.88
LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. J Cell Biol (2010) 1.79
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol (2009) 1.79
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Dendrimers in gene delivery. Adv Drug Deliv Rev (2005) 1.73
Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell (2013) 1.72
ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. Dev Cell (2010) 1.68
Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut (2010) 1.67
p53-mediated induction of Noxa and p53AIP1 requires NFkappaB. Cell Cycle (2010) 1.67
Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol Cell (2013) 1.65
Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene (2004) 1.64
Phosphorylation of HDM2 by Akt. Oncogene (2002) 1.63
The multiple roles of autophagy in cancer. Carcinogenesis (2011) 1.63
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP. Genes Dev (2010) 1.61
DRAM links autophagy to p53 and programmed cell death. Autophagy (2007) 1.60
Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res (2013) 1.58
Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem (2012) 1.58
p53, ROS and senescence in the control of aging. Aging (Albany NY) (2010) 1.56
Forceps delivery volumes in teaching and nonteaching hospitals: are volumes sufficient for physicians to acquire and maintain competence? Acad Med (2014) 1.55
Female ground tits prefer relatives as extra-pair partners: driven by kin-selection? Mol Ecol (2011) 1.54
A boosting approach for motif modeling using ChIP-chip data. Bioinformatics (2005) 1.53
Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol (2003) 1.51
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells? BJU Int (2012) 1.51
The Lats2 tumor suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic function of ASPP1. Genes Dev (2010) 1.50
Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta (2009) 1.50
Insurance status and the transfer of hospitalized patients: an observational study. Ann Intern Med (2014) 1.49
ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev (2006) 1.49
Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation. Cell Cycle (2010) 1.47
Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. Carcinogenesis (2005) 1.46
To die or not to die: how does p53 decide? Oncogene (2004) 1.45
A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst (2009) 1.43
The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med (2009) 1.43
Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta (2008) 1.43
Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest (2011) 1.42
Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41
Adverse outcomes in hip arthroplasty: long-term trends. J Bone Joint Surg Am (2012) 1.40
RPLC-ion-trap-FTMS method for lipid profiling of plasma: method validation and application to p53 mutant mouse model. J Proteome Res (2008) 1.40
Autophagy and cancer--issues we need to digest. J Cell Sci (2012) 1.39
The impact of hospital cardiac specialization on outcomes after coronary artery bypass graft surgery: analysis of medicare claims data. Circ Cardiovasc Qual Outcomes (2010) 1.39